Compare Globus Medical Inc. Class A Common Stock (GMED) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Novagold Resources Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Novagold Resources Inc. trades at $6.32 (market cap $2.90B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.5× Novagold Resources Inc.'s market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Novagold Resources Inc. for 0 Days on average.
| GMED | NG | |
|---|---|---|
Market Cap | $10.25B | $2.90B |
Volume | 1,108,124 | 3,973,464 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $14.20 |
52-Week Low | $58.33 | $5.18 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.76B | $2.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
